Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Correction to: Genetically downregulated Interleukin-6 signalling is associated with a lower risk of frailtyAge and ageing, 2023-03, Vol.52 (3) [Peer Reviewed Journal]The Author(s) 2023. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com ;ISSN: 0002-0729 ;EISSN: 1468-2834 ;DOI: 10.1093/ageing/afad036 ;PMID: 36860177Full text available |
|
2 |
Material Type: Article
|
POS0860 COMPARING THE EFFICACY OF THE BDMARD SWITCHER GROUP AND JAK CYCLER GROUP IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH FAILURE TO THE JAK INHIBITORSAnnals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.734-735 [Peer Reviewed Journal]2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.5422Full text available |
|
3 |
Material Type: Article
|
Corrigendum: IL-6 as a keystone cytokine in health and diseaseNature immunology, 2017-11, Vol.18 (11), p.1271-1271 [Peer Reviewed Journal]COPYRIGHT 2017 Nature Publishing Group ;COPYRIGHT 2017 Nature Publishing Group ;Copyright Nature Publishing Group Nov 2017 ;ISSN: 1529-2908 ;EISSN: 1529-2916 ;DOI: 10.1038/ni1117-1271b ;PMID: 29044237Full text available |
|
4 |
Material Type: Article
|
Rapid endotheliitis and vascular damage characterize SARS‐CoV‐2 infection in a human lung‐on‐chip modelEMBO reports, 2021-06, Vol.22 (6), p.e52744-n/a [Peer Reviewed Journal]2021 The Authors ;This article is protected by copyright. All rights reserved. ;2021 EMBO ;ISSN: 1469-221X ;EISSN: 1469-3178 ;DOI: 10.15252/embr.202152744 ;PMID: 33908688Full text available |
|
5 |
Material Type: Article
|
Issue InformationThe FEBS journal, 2022-10, Vol.289 (19), p.5715-5717 [Peer Reviewed Journal]Copyright © 2022 Federation of European Biochemical Societies ;ISSN: 1742-464X ;EISSN: 1742-4658 ;DOI: 10.1111/febs.16003Full text available |
|
6 |
Material Type: Article
|
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cellsNature medicine, 2018-06, Vol.24 (6), p.739-748 [Peer Reviewed Journal]COPYRIGHT 2018 Nature Publishing Group ;COPYRIGHT 2018 Nature Publishing Group ;Copyright Nature Publishing Group Jun 2018 ;ISSN: 1078-8956 ;EISSN: 1546-170X ;DOI: 10.1038/s41591-018-0036-4 ;PMID: 29808007Full text available |
|
7 |
Material Type: Article
|
COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020-03, Vol.395 (10229), p.1033-1034 [Peer Reviewed Journal]2020 Elsevier Ltd ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.elsevier.com/legal/elsevier-website-terms-and-conditions ;2020. Elsevier Ltd ;2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)30628-0 ;PMID: 32192578Digital Resources/Online E-Resources |
|
8 |
Material Type: Article
|
Correction: Synthesis of IL-6 by Hepatocytes Is a Normal Response to Common Hepatic StimuliPloS one, 2019-10, Vol.14 (10), p.e0224498-e0224498 [Peer Reviewed Journal]2019 Norris et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2019 Norris et al 2019 Norris et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0224498 ;PMID: 31644563Full text available |
|
9 |
Material Type: Article
|
Targeting the IL-6/JAK/STAT3 signalling axis in cancerNature reviews. Clinical oncology, 2018-04, Vol.15 (4), p.234-248 [Peer Reviewed Journal]COPYRIGHT 2018 Nature Publishing Group ;COPYRIGHT 2018 Nature Publishing Group ;Copyright Nature Publishing Group Apr 2018 ;ISSN: 1759-4774 ;EISSN: 1759-4782 ;DOI: 10.1038/nrclinonc.2018.8 ;PMID: 29405201Full text available |
|
10 |
Material Type: Article
|
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemiaNature medicine, 2018-05, Vol.24 (5), p.563-571 [Peer Reviewed Journal]COPYRIGHT 2018 Nature Publishing Group ;Copyright Nature Publishing Group May 2018 ;The Author(s) 2018. ;ISSN: 1078-8956 ;EISSN: 1546-170X ;DOI: 10.1038/s41591-018-0010-1 ;PMID: 29713085Full text available |
|
11 |
Material Type: Article
|
Translating IL-6 biology into effective treatmentsNature reviews. Rheumatology, 2020-06, Vol.16 (6), p.335-345 [Peer Reviewed Journal]COPYRIGHT 2020 Nature Publishing Group ;Springer Nature Limited 2020. ;Springer Nature Limited 2020 ;ISSN: 1759-4790 ;EISSN: 1759-4804 ;DOI: 10.1038/s41584-020-0419-z ;PMID: 32327746Full text available |
|
12 |
Material Type: Article
|
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockadeNature medicine, 2018-06, Vol.24 (6), p.731-738 [Peer Reviewed Journal]COPYRIGHT 2018 Nature Publishing Group ;COPYRIGHT 2018 Nature Publishing Group ;Copyright Nature Publishing Group Jun 2018 ;The Author(s) 2018. ;ISSN: 1078-8956 ;EISSN: 1546-170X ;DOI: 10.1038/s41591-018-0041-7 ;PMID: 29808005Full text available |
|
13 |
Material Type: Article
|
Overactivation of IL6 cis‑signaling in leukocytes is an inflammatory hallmark of deep vein thrombosisMolecular medicine reports, 2022-04, Vol.25 (4), Article 136COPYRIGHT 2022 Spandidos Publications ;Copyright Spandidos Publications UK Ltd. 2022 ;ISSN: 1791-2997 ;EISSN: 1791-3004 ;DOI: 10.3892/mmr.2022.12652 ;PMID: 35191519Full text available |
|
14 |
Material Type: Article
|
POS0862 PRESCRIPTION PATTERN OF JAK INHIBITORS OVER 5 YEARS IN ITALY: DATA FROM THE ITALIAN NATIONAL GISEA REGISTRYAnnals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.735-736 [Peer Reviewed Journal]2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.5537Full text available |
|
15 |
Material Type: Article
|
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trialNature medicine, 2022-06, Vol.28 (6), p.1256-1268 [Peer Reviewed Journal]2022. Crown. ;Crown 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Crown 2022 ;ISSN: 1078-8956 ;EISSN: 1546-170X ;DOI: 10.1038/s41591-022-01789-0 ;PMID: 35589854Full text available |
|
16 |
Material Type: Article
|
Pharmaco-Immunomodulatory Therapy in COVID-19Drugs (New York, N.Y.), 2020-09, Vol.80 (13), p.1267-1292 [Peer Reviewed Journal]Springer Nature Switzerland AG 2020 ;Copyright Springer Nature B.V. Sep 2020 ;ISSN: 0012-6667 ;EISSN: 1179-1950 ;DOI: 10.1007/s40265-020-01367-z ;PMID: 32696108Full text available |
|
17 |
Material Type: Article
|
POS0639 SWITCHING FROM IL-6R ANTAGONISTS TO OLOKIZUMAB, A DIRECT IL-6 INHIBITORAnnals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.595-596 [Peer Reviewed Journal]2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.1839Full text available |
|
18 |
Material Type: Article
|
Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosisAnnals of the rheumatic diseases, 2018-09, Vol.77 (9), p.1362-1371 [Peer Reviewed Journal]Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ;2018 Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. 2018 ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-213031 ;PMID: 29853453Full text available |
|
19 |
Material Type: Article
|
257 IL-6 trans-signaling causes accelerated atherosclerosis in disease-prone animalsRheumatology (Oxford, England), 2018-04, Vol.57 (suppl_3) [Peer Reviewed Journal]The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2018 ;The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com ;ISSN: 1462-0324 ;EISSN: 1462-0332 ;DOI: 10.1093/rheumatology/key075.481Full text available |
|
20 |
Material Type: Article
|
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release SyndromeThe oncologist (Dayton, Ohio), 2018-08, Vol.23 (8), p.943-947 [Peer Reviewed Journal]Published 2018. This article is a U.S. Government work and is in the public domain in the USA ;Published 2018. This article is a U.S. Government work and is in the public domain in the USA. ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1634/theoncologist.2018-0028 ;PMID: 29622697Full text available |